Axcelis Q3 Profit Plunges 46% Amidst Weakening Product Demand
Ticker: ACLS · Form: 10-Q · Filed: Nov 6, 2025 · CIK: 1113232
Sentiment: bearish
Topics: Semiconductor Equipment, Ion Implantation, Revenue Decline, Net Income Drop, Q3 Earnings, Technology Sector, Capital Equipment
Related Tickers: ACLS, AMAT, LRCX
TL;DR
**Axcelis's Q3 numbers are a red flag; revenue and profit are tanking, signaling a tough road ahead for semiconductor equipment.**
AI Summary
Axcelis Technologies Inc. reported a significant decline in financial performance for the three and nine months ended September 30, 2025, primarily driven by reduced product revenue. Total revenue for the three months decreased by 16.8% to $213.6 million from $256.6 million in the prior year, and for the nine months, it fell by 21.5% to $600.7 million from $765.4 million. Net income saw an even steeper decline, dropping 46.5% to $26.0 million for the three months from $48.6 million, and 43.1% to $85.9 million for the nine months from $151.0 million. Diluted EPS followed suit, decreasing to $0.83 from $1.49 for the quarter and to $2.70 from $4.61 for the nine-month period. The company's cash and cash equivalents increased to $187.5 million from $123.5 million at December 31, 2024, while short-term investments decreased significantly to $262.1 million from $447.8 million. A key business change was the reclassification of held-to-maturity securities to available-for-sale in February 2025, following a $199.5 million sale. Risks include declining product demand and potential impacts on inventory management, as inventories increased to $324.3 million from $282.2 million. The strategic outlook appears challenged by the substantial revenue and profit contraction.
Why It Matters
This significant downturn in Axcelis's revenue and net income signals a challenging environment for semiconductor equipment manufacturers, impacting investor confidence and potentially future R&D investments. The 46.5% drop in quarterly net income and 21.5% decline in nine-month revenue could lead to a re-evaluation of ACLS's growth trajectory and valuation by investors. For employees, sustained revenue declines could eventually lead to workforce adjustments, while customers might see shifts in product availability or pricing strategies. In the broader market, this performance reflects potential softening in the semiconductor industry, which could affect competitors like Applied Materials and Lam Research, and the overall tech sector.
Risk Assessment
Risk Level: high — The company experienced a 46.5% decrease in net income for the three months ended September 30, 2025, to $25.986 million from $48.576 million in the prior year. Product revenue also declined significantly by 18.5% to $201.218 million from $246.826 million for the same period, indicating a substantial weakening in core business performance and demand.
Analyst Insight
Investors should consider reducing exposure to ACLS given the sharp decline in revenue and net income, which suggests a deteriorating market for semiconductor equipment. Monitor upcoming earnings calls for management's outlook on demand and any strategic shifts to address the significant revenue contraction.
Financial Highlights
- revenue
- $213,611,000
- operating Margin
- 11.7%
- net Income
- $25,986,000
- eps
- $0.83
- gross Margin
- 41.6%
- cash Position
- $187,501,000
- revenue Growth
- -16.8%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Product | $201,218,000 | -18.5% |
| Services | $12,393,000 | +27.3% |
Key Numbers
- $213.6M — Total Revenue (Q3 2025) (Decreased 16.8% from $256.6M in Q3 2024)
- $600.7M — Total Revenue (9M 2025) (Decreased 21.5% from $765.4M in 9M 2024)
- $26.0M — Net Income (Q3 2025) (Decreased 46.5% from $48.6M in Q3 2024)
- $85.9M — Net Income (9M 2025) (Decreased 43.1% from $151.0M in 9M 2024)
- $0.83 — Diluted EPS (Q3 2025) (Decreased from $1.49 in Q3 2024)
- $2.70 — Diluted EPS (9M 2025) (Decreased from $4.61 in 9M 2024)
- $187.5M — Cash and Cash Equivalents (Sep 30, 2025) (Increased from $123.5M at Dec 31, 2024)
- $324.3M — Inventories, net (Sep 30, 2025) (Increased from $282.2M at Dec 31, 2024)
- $199.5M — Sale of Held-to-Maturity Securities (Feb 2025) (Led to reclassification of remaining securities to available-for-sale)
- 30,999,133 — Common Stock Outstanding (Nov 3, 2025) (Reflects share repurchases)
Key Players & Entities
- AXCELIS TECHNOLOGIES INC (company) — registrant
- Bloomberg (company) — publisher
- SEC (regulator) — filing authority
- Nasdaq Global Select Market (company) — exchange where ACLS is listed
- Applied Materials (company) — competitor
- Lam Research (company) — competitor
- $213.6 million (dollar_amount) — total revenue for three months ended September 30, 2025
- $256.6 million (dollar_amount) — total revenue for three months ended September 30, 2024
- $26.0 million (dollar_amount) — net income for three months ended September 30, 2025
- $48.6 million (dollar_amount) — net income for three months ended September 30, 2024
FAQ
What were Axcelis Technologies Inc.'s total revenues for the three and nine months ended September 30, 2025?
Axcelis Technologies Inc.'s total revenue for the three months ended September 30, 2025, was $213.611 million, a decrease from $256.564 million in the prior year. For the nine months ended September 30, 2025, total revenue was $600.718 million, down from $765.448 million in the same period of 2024.
How did Axcelis Technologies Inc.'s net income change for the recent quarter?
Axcelis Technologies Inc.'s net income for the three months ended September 30, 2025, was $25.986 million, a significant decrease of 46.5% compared to $48.576 million for the same period in 2024.
What was the diluted earnings per share (EPS) for Axcelis Technologies Inc. in Q3 2025?
The diluted earnings per share for Axcelis Technologies Inc. for the three months ended September 30, 2025, was $0.83, a decrease from $1.49 in the corresponding period of 2024.
What was the change in Axcelis Technologies Inc.'s cash and cash equivalents as of September 30, 2025?
As of September 30, 2025, Axcelis Technologies Inc. reported cash and cash equivalents of $187.501 million, an increase from $123.512 million as of December 31, 2024.
Did Axcelis Technologies Inc. make any significant changes to its investment classifications?
Yes, in February 2025, Axcelis Technologies Inc. sold $199.5 million of securities classified as held-to-maturity. This sale led to the reclassification of the remaining held-to-maturity securities as available-for-sale, resulting in a remeasurement increase in short-term investments of $81.0 thousand.
How much stock-based compensation expense did Axcelis Technologies Inc. recognize?
Axcelis Technologies Inc. recognized stock-based compensation expense of $5.3 million for the three months ended September 30, 2025, and $15.7 million for the nine months ended September 30, 2025.
What are the primary risks highlighted in Axcelis Technologies Inc.'s 10-Q filing?
The filing implicitly highlights risks related to declining product demand, evidenced by the 18.5% drop in product revenue for the quarter. Additionally, an increase in inventories to $324.342 million from $282.225 million at December 31, 2024, suggests potential inventory management risks if demand continues to soften.
What is Axcelis Technologies Inc.'s business model?
Axcelis Technologies Inc. is a producer of ion implantation equipment used in the fabrication of semiconductor chips. The company also provides extensive worldwide aftermarket service and support, including spare parts, equipment upgrades, used equipment, and maintenance services to the semiconductor industry.
How many shares of common stock were outstanding for Axcelis Technologies Inc. as of November 3, 2025?
As of November 3, 2025, there were 30,999,133 shares of Axcelis Technologies Inc.'s common stock outstanding.
What was the gross profit for Axcelis Technologies Inc. for the nine months ended September 30, 2025?
For the nine months ended September 30, 2025, Axcelis Technologies Inc. reported a gross profit of $264.916 million, a decrease from $338.431 million in the same period of 2024.
Risk Factors
- Declining Product Demand [high — market]: The company experienced a significant decline in product revenue, down 18.5% for the quarter. This suggests a potential decrease in demand for its ion implantation equipment, which could impact future sales and profitability.
- Inventory Management Challenges [medium — operational]: Inventories increased to $324.3 million from $282.2 million. This rise, coupled with declining revenue, indicates potential challenges in managing inventory levels and could lead to increased carrying costs or obsolescence.
- Reduced Profitability [high — financial]: Net income for the quarter fell by 46.5% to $26.0 million. This substantial decrease in profitability, driven by lower revenues and potentially higher costs relative to revenue, poses a financial risk.
- Investment Portfolio Reclassification [medium — financial]: The company reclassified held-to-maturity securities to available-for-sale after a $199.5 million sale. While this may offer more flexibility, it also exposes the company to potential market fluctuations in the value of these investments.
Industry Context
Axcelis Technologies operates in the semiconductor equipment manufacturing industry, specifically focusing on ion implantation. This sector is cyclical and highly dependent on capital expenditures by chip manufacturers. Recent trends indicate a slowdown in demand for certain types of semiconductor equipment, potentially due to market saturation or shifts in technology focus.
Regulatory Implications
As a publicly traded company, Axcelis must comply with SEC regulations, including accurate financial reporting and disclosures. The reclassification of investments and the reporting of significant revenue and profit declines are subject to scrutiny to ensure compliance with accounting standards and investor protection rules.
What Investors Should Do
- Monitor product order backlog and future guidance
- Analyze inventory turnover ratio
- Evaluate the impact of investment reclassification
Key Dates
- 2025-02-01: Sale of Held-to-Maturity Securities — A $199.5 million sale of securities led to the reclassification of remaining investments to available-for-sale, impacting the company's investment strategy and risk exposure.
- 2025-09-30: End of Third Quarter — Reported significant declines in revenue and net income, highlighting current business challenges.
- 2024-12-31: End of Fiscal Year 2024 — Provided the comparative balance sheet figures for the current period's assets and liabilities.
Glossary
- Ion Implantation Equipment
- Machinery used in semiconductor manufacturing to introduce ions into a material, a critical step in creating integrated circuits. (This is the core product of Axcelis Technologies, and its demand directly impacts the company's revenue.)
- Available-for-Sale Investments
- Investments that are not classified as held-to-maturity or trading securities. Their unrealized gains and losses are reported in other comprehensive income. (Axcelis reclassified its investments to this category, making their valuation subject to market fluctuations.)
- Held-to-Maturity Securities
- Debt securities that a company has the intent and ability to hold until their maturity date. They are recorded at amortized cost. (Axcelis sold a significant portion of these securities, leading to a change in its investment classification.)
- Diluted EPS
- Earnings per share calculated by dividing net income by the total number of diluted common shares outstanding, including the effect of stock options and convertible securities. (A key profitability metric for investors, which has seen a substantial decrease for Axcelis.)
Year-Over-Year Comparison
Compared to the prior year's nine-month period, Axcelis Technologies has experienced a significant downturn. Total revenue has decreased by 21.5% from $765.4 million to $600.7 million, and net income has fallen by 43.1% from $151.0 million to $85.9 million. Diluted EPS has also declined substantially. While cash and cash equivalents have increased, this is offset by a decrease in short-term investments and a notable rise in inventories, indicating potential headwinds and a more challenging operating environment than previously reported.
Filing Stats: 4,481 words · 18 min read · ~15 pages · Grade level 16.1 · Accepted 2025-11-06 15:37:06
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value ACLS Nasdaq Global Select
Filing Documents
- acls-20250930x10q.htm (10-Q) — 2145KB
- acls-20250930xex31d1.htm (EX-31.1) — 12KB
- acls-20250930xex31d2.htm (EX-31.2) — 13KB
- acls-20250930xex32d1.htm (EX-32.1) — 7KB
- acls-20250930xex32d2.htm (EX-32.2) — 7KB
- 0001104659-25-107689.txt ( ) — 8464KB
- acls-20250930.xsd (EX-101.SCH) — 47KB
- acls-20250930_cal.xml (EX-101.CAL) — 79KB
- acls-20250930_def.xml (EX-101.DEF) — 166KB
- acls-20250930_lab.xml (EX-101.LAB) — 439KB
- acls-20250930_pre.xml (EX-101.PRE) — 312KB
- acls-20250930x10q_htm.xml (XML) — 1565KB
- FINANCIAL INFORMATION
PART I - FINANCIAL INFORMATION Item 1.
Financial Statements (Unaudited)
Financial Statements (Unaudited) Consolidated Statements of Operations for the three and nine months ended September 30, 2025 and 2024 3 Consolidated Statements of Comprehensive Income for the three and nine months ended September 30, 2025 and 2024 4 Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 5 Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2025 and 2024 6 Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 8
Notes to Consolidated Financial Statements (Unaudited)
Notes to Consolidated Financial Statements (Unaudited) 9 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Overview 22 Critical Accounting Estimates 23 Results of Operations 24 Liquidity and Capital Resources 30 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 31 Item 4.
Controls and Procedures
Controls and Procedures 31
- OTHER INFORMATION
PART II - OTHER INFORMATION 32 Item 1.
Legal Proceedings
Legal Proceedings 32 Item 1A.
Risk Factors
Risk Factors 32 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities 34 Item 3. Defaults Upon Senior Securities 34 Item 4. Mine Safety Disclosures 34 Item 5. Other Information 34 Item 6. Exhibits 35 2 Table of Contents PART 1—FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements. Axcelis Technologies, Inc. Consolidated Statements of Operations (In thousands, except per share amounts) (Unaudited) Three months ended Nine months ended September 30, September 30, 2025 2024 2025 2024 Revenue: Product $ 201,218 $ 246,826 $ 567,444 $ 735,626 Services 12,393 9,738 33,274 29,822 Total revenue 213,611 256,564 600,718 765,448 Cost of revenue: Product 112,078 136,379 302,041 399,049 Services 12,727 10,215 33,761 27,968 Total cost of revenue 124,805 146,594 335,802 427,017 Gross profit 88,806 109,970 264,916 338,431 Operating expenses: Research and development 24,640 26,395 78,832 77,843 Sales and marketing 15,838 16,808 45,965 51,483 General and administrative 23,308 19,854 56,976 52,842 Total operating expenses 63,786 63,057 181,773 182,168 Income from operations 25,020 46,913 83,143 156,263 Other income (expense): Interest income 5,465 6,560 16,547 18,126 Interest expense ( 1,305 ) ( 1,333 ) ( 4,028 ) ( 4,017 ) Other, net 970 3,225 2,569 1,257 Total other income 5,130 8,452 15,088 15,366 Income before income taxes 30,150 55,365 98,231 171,629 Income tax provision 4,164 6,789 12,290 20,593 Net income $ 25,986 $ 48,576 $ 85,941 $ 151,036 Net income per share: Basic $ 0.83 $ 1.49 $ 2.70 $ 4.63 Diluted $ 0.83 $ 1.49 $ 2.70 $ 4.61 Shares used in computing net income per share: Basic weighted average shares of common stock 31,287 32,550 31,796 32,595 Diluted weighted average shares of common stock 31,450 32,675 31,863 32,780 See accompanying Notes to these Consolidated Financial Statements (Unaudited) 3 Table of Contents Axcelis Technologies, Inc. Consolidated Statements of Comprehensive Income (In thousands) (Unaudited) Three months ended Nine months ended Septembe
Notes to Consolidated Financial Statements (Unaudited)
Notes to Consolidated Financial Statements (Unaudited) Note 1. Nature of Business Axcelis Technologies, Inc. ("Axcelis" or the "Company") was incorporated in Delaware in 1995 and is a producer of ion implantation equipment used in the fabrication of semiconductor chips in the United States, Europe and Asia. In addition, we provide extensive worldwide aftermarket service and support, including spare parts, equipment upgrades, used equipment, and maintenance services to the semiconductor industry. The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments which are of a normal recurring nature and considered necessary for a fair presentation of these financial statements have been included. Operating results for the interim periods presented are not necessarily indicative of the results that may be expected for other interim periods or for the year as a whole. The balance sheet at December 31, 2024 has been derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. As of September 30, 2025, there have been no material changes in the Company's significant accounting policies, other than as described in Note 2 below. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 (the "2024 Form 10-K"). Note 2. Significant Accounting Policies Cash, Cash Equivalents, Short-term Investments, and Long-t